251 related articles for article (PubMed ID: 21279815)
21. Has bevacizumab (Avastin) given extra therapeutic gain in metastatic colorectal cancer and malignant brain gliomas? Systematic review answering this question.
Koukourakis GV
Recent Pat Inflamm Allergy Drug Discov; 2012 Jan; 6(1):70-7. PubMed ID: 22022926
[TBL] [Abstract][Full Text] [Related]
22. Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab.
Pope WB; Xia Q; Paton VE; Das A; Hambleton J; Kim HJ; Huo J; Brown MS; Goldin J; Cloughesy T
Neurology; 2011 Feb; 76(5):432-7. PubMed ID: 21282590
[TBL] [Abstract][Full Text] [Related]
23. Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches.
Beal K; Abrey LE; Gutin PH
Radiat Oncol; 2011 Jan; 6():2. PubMed ID: 21214925
[TBL] [Abstract][Full Text] [Related]
24. The use of O-(2-18F-fluoroethyl)-L-tyrosine PET for treatment management of bevacizumab and irinotecan in patients with recurrent high-grade glioma: a cost-effectiveness analysis.
Heinzel A; Müller D; Langen KJ; Blaum M; Verburg FA; Mottaghy FM; Galldiks N
J Nucl Med; 2013 Aug; 54(8):1217-22. PubMed ID: 23785172
[TBL] [Abstract][Full Text] [Related]
25. Change in pattern of relapse after antiangiogenic therapy in high-grade glioma.
Narayana A; Kunnakkat SD; Medabalmi P; Golfinos J; Parker E; Knopp E; Zagzag D; Eagan P; Gruber D; Gruber ML
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):77-82. PubMed ID: 21163583
[TBL] [Abstract][Full Text] [Related]
26. Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice.
de Groot JF; Fuller G; Kumar AJ; Piao Y; Eterovic K; Ji Y; Conrad CA
Neuro Oncol; 2010 Mar; 12(3):233-42. PubMed ID: 20167811
[TBL] [Abstract][Full Text] [Related]
27. High-grade glioma before and after treatment with radiation and Avastin: initial observations.
Fischer I; Cunliffe CH; Bollo RJ; Raza S; Monoky D; Chiriboga L; Parker EC; Golfinos JG; Kelly PJ; Knopp EA; Gruber ML; Zagzag D; Narayana A
Neuro Oncol; 2008 Oct; 10(5):700-8. PubMed ID: 18697955
[TBL] [Abstract][Full Text] [Related]
28. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Mrugala MM
Neurology; 2009 Feb; 72(8):773; author reply 773-4. PubMed ID: 19248218
[No Abstract] [Full Text] [Related]
29. Bevacizumab: a treatment option for recurrent glioblastoma multiforme.
Buie LW; Valgus J
Ann Pharmacother; 2008 Oct; 42(10):1486-90. PubMed ID: 18765835
[TBL] [Abstract][Full Text] [Related]
30. Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors.
Scott BJ; Quant EC; McNamara MB; Ryg PA; Batchelor TT; Wen PY
Neuro Oncol; 2010 Jun; 12(6):603-7. PubMed ID: 20156808
[TBL] [Abstract][Full Text] [Related]
31. Bevacizumab for Patients with Recurrent Multifocal Glioblastomas.
Burger MC; Breuer S; Cieplik HC; Harter PN; Franz K; Bähr O; Steinbach JP
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29156610
[TBL] [Abstract][Full Text] [Related]
32. Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma.
Verhoeff JJC; Lavini C; van Linde ME; Stalpers LJA; Majoie CBLM; Reijneveld JC; van Furth WR; Richel DJ
Ann Oncol; 2010 Aug; 21(8):1723-1727. PubMed ID: 20064829
[TBL] [Abstract][Full Text] [Related]
33. Bevacizumab for Malignant Brain Gliomas. Which is the Current Evidence?
Koukourakis GV
Recent Pat Inflamm Allergy Drug Discov; 2015; 9(2):136-43. PubMed ID: 26256461
[TBL] [Abstract][Full Text] [Related]
34. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O
Cloughesy T; Finocchiaro G; Belda-Iniesta C; Recht L; Brandes AA; Pineda E; Mikkelsen T; Chinot OL; Balana C; Macdonald DR; Westphal M; Hopkins K; Weller M; Bais C; Sandmann T; Bruey JM; Koeppen H; Liu B; Verret W; Phan SC; Shames DS
J Clin Oncol; 2017 Jan; 35(3):343-351. PubMed ID: 27918718
[TBL] [Abstract][Full Text] [Related]
35. [Monoclonal antibodies in high-grade gliomas].
Chekhonin IV; Leopold AV; Gurina OI; Semenova AV
Vestn Ross Akad Med Nauk; 2014; (9-10):131-9. PubMed ID: 25816654
[TBL] [Abstract][Full Text] [Related]
36. Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas.
Chamberlain MC
Cancer; 2010 Sep; 116(17):3988-99. PubMed ID: 20564141
[TBL] [Abstract][Full Text] [Related]
37. Antiangiogenic therapy in malignant gliomas.
Norden AD; Drappatz J; Wen PY
Curr Opin Oncol; 2008 Nov; 20(6):652-61. PubMed ID: 18841047
[TBL] [Abstract][Full Text] [Related]
38. Bevacizumab alone or in combination with irinotecan in recurrent WHO grade II and grade III gliomas.
Seystahl K; Wiestler B; Hundsberger T; Happold C; Wick W; Weller M; Wick A
Eur Neurol; 2013; 69(2):95-101. PubMed ID: 23182901
[TBL] [Abstract][Full Text] [Related]
39. Detection of failure of bevacizumab treatment for malignant glioma based on urinary matrix metalloproteinase activity.
Takano S; Mashiko R; Osuka S; Ishikawa E; Ohneda O; Matsumura A
Brain Tumor Pathol; 2010 Oct; 27(2):89-94. PubMed ID: 21046310
[TBL] [Abstract][Full Text] [Related]
40. Angiogenic inhibition in high-grade gliomas: past, present and future.
Jo J; Schiff D; Purow B
Expert Rev Neurother; 2012 Jun; 12(6):733-47. PubMed ID: 22650175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
